IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
In the year to March 31 2008, the Pharmaceuticals seg ment re corded net sales of Yen1,272 bil lion, up
5.8% from Yen1,203 bil lion in the year-ear lier pe riod and rep re sent ing 92.5% of to tal sales. Eth i cal drug
sales grew by 5.8% to Yen1,210.2 bil lion (88% of to tal sales) from Yen1,144.1 bil lion the pre vi ous year,
of which Yen529.7 bil lion (up 2.9%) was gen er ated in Ja pan (38.5% of to tal sales), and Yen680.6 bil lion
(up 8.2%) was gen er ated over seas (49.5% of total sales).
To tal sales of the four global stra te gic prod ucts were: Yen396.2 bil lion for Actos (pioglitazone), up
17.8%; Yen223.1 bil lion for Blopress (candesartan), up 8.2% Yen148.7 bil lion for Takepron
(lansoprazole), down 1.4% and Yen124.0 bil lion for Leuplin (leuprorelin) down 2.7%.
Do mes tic sales of Blopress were Yen137.1 bil lion (up 6.1%); Yen66.4 bil lion for Leuplin (up 3.3%);
Yen64.8 bil lion (up 11.8%) for Takepron; Yen41.6 bil lion for Actos (up 23.6%) while a 5.2% de cline in
sales of Basen (voglibose) to Yen52.8 bil lion was re corded due to the en try of generics and other un fa vor -
able factors.
The US mar ket saw a 17.7% rise in sales of Actos to $2.79 bil lion while sales of new con sti pa tion drug
Amitiza more than tri pled its sales to $171 mil lion and Rozerem for in som nia jumped 25% to $111 million
The Con sumer Healthcare busi ness posted a 5.3% in crease in sales from Yen58.7 bil lion to Yen61.8 bil -
lion in the 12 months to March 2008, rep re sent ing 4.5% of to tal sales.
Net sales in the Other seg ment in creased slightly by 0.4% from Yen102.4 bil lion to Yen102.7 bil lion in the
12 months to March 2008.
Yen billions
1,400
1,200
1,000
800
600
400
200
0
Source: Takeda Annual Reports
Sales by Business Sector
2004 2005 2006 2007 2008
Pharmaceuticals Other
© 2009 IMS Health In cor po rated or its af fil i ates Page 17